#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Ouzama Henry Email
VP Clinical Development . Dynavax Technologies
How to contact Ouzama Henry
Join and see Ouzama's contact info for free!Current Roles
Employees:
423Revenue:
$91.8MAbout
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company?s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development.Dynavax Technologies Address
2100 Powell Streetnull, null